Shuichi Aoki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shuichi Aoki has a total of 212 co-authors. Here are the top co-authors by number of shared publications:
- Dan Gabriel Duda
Edwin. L. Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, USA
64 shared publications - Alexei Hernandez
Johns Hopkins University 1 Department of Oncology, Sidney Kimmel Comprehensive Cancer Center Baltimore, Maryland
61 shared publications - Aya Matsui
Edwin L. Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
61 shared publications - Dai Fukumura
Department of Radiation Oncology, Edwin L. Steele Laboratories, Massachusetts General Hospital and Harvard Medical School
61 shared publications - Daniel Staiculescu
Edwin L. Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
61 shared publications - Jiang Chen
Department of General Surgery, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China
61 shared publications
Latest Publications
- Open Access
- 18 September 2026
- Published by Elsevier in Surgery in Practice and Science
The modified Blumgart anastomosis is associated with a lower incidence of clinically relevant postoperative pancreatic fistula and a shorter anastomotic time: a prospective cohort study with a historical control group
- 18 September 2026
- Published by Elsevier in Surgery in Practice and Science
Open AccessThe modified Blumgart anastomosis is associated with a lower incidence of clinically relevant postoperative pancreatic fistula and a shorter anastomotic time: a prospective cohort study with a historical control group
- Open Access
- 18 September 2026
- Published by Open Exploration Publishing in Exploration of Targeted Anti-tumor Therapy
- Vol. 7, 1002402
Significance of next-generation sequencing in the era of targeted therapy for biliary tract cancer: an analysis at a single institution
Aim: Treatment approaches for biliary tract cancer (BTC) vary widely. Genomic profiling through next-generation sequencing (NGS) has made it possible to apply precision medicine in the management of BTC. This retrospective observational study aimed to evaluate the implementation of treatments based on identified genomic mutations and their clinical significance in patients with BTC in Japan, where NGS is covered by health insurance. Methods: We conducted a retrospective analysis of 65 patients with unresectable or recurrent BTC who underwent comprehensive genomic profiling at a single institution between November 2019 and October 2024. Genomic mutations were classified according to the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) scale. Overall survival (OS) was estimated using the Kaplan-Meier method and compared using the log-rank test. Results: Among the 65 patients, clinically relevant genomic mutations classified using the ESCAT scale were identified in 47 patients, and clinically treatable genomic mutations were identified in 13 patients. Six patients ultimately received mutation-guided therapy, including fibroblast growth factor receptor inhibitors and pembrolizumab. The median time from specimen submission to review by the expert panel was 26 (range, 16–40) days. No significant difference in OS was observed based on the site of the primary tumor (log-rank test, P = 0.5804). Conclusions: Although clinically actionable genomic mutations were identified in one-fifth of patients, < 10% ultimately received treatment based on those findings, highlighting a gap between genomic profiling and treatment implementation. In contrast, with the increasing number of available therapies, access to precision treatment for patients with BTC may improve in the future through a combination of early adoption of NGS and the complementary use of liquid biopsy when tissue is unavailable.
- 18 September 2026
- Published by Open Exploration Publishing in Exploration of Targeted Anti-tumor Therapy
- Vol. 7, 1002402
Open AccessSignificance of next-generation sequencing in the era of targeted therapy for biliary tract cancer: an analysis at a single institution
Aim: Treatment approaches for biliary tract cancer (BTC) vary widely. Genomic profiling through next-generation sequencing (NGS) has made it possible to apply precision medicine in the management of BTC. This retrospective observational study aimed to evaluate the implementation of treatments based on identified genomic mutations and their clinical significance in patients with BTC in Japan, where NGS is covered by health insurance. Methods: We conducted a retrospective analysis of 65 patients with unresectable or recurrent BTC who underwent comprehensive genomic profiling at a single institution between November 2019 and October 2024. Genomic mutations were classified according to the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) scale. Overall survival (OS) was estimated using the Kaplan-Meier method and compared using the log-rank test. Results: Among the 65 patients, clinically relevant genomic mutations classified using the ESCAT scale were identified in 47 patients, and clinically treatable genomic mutations were identified in 13 patients. Six patients ultimately received mutation-guided therapy, including fibroblast growth factor receptor inhibitors and pembrolizumab. The median time from specimen submission to review by the expert panel was 26 (range, 16–40) days. No significant difference in OS was observed based on the site of the primary tumor (log-rank test, P = 0.5804). Conclusions: Although clinically actionable genomic mutations were identified in one-fifth of patients, < 10% ultimately received treatment based on those findings, highlighting a gap between genomic profiling and treatment implementation. In contrast, with the increasing number of available therapies, access to precision treatment for patients with BTC may improve in the future through a combination of early adoption of NGS and the complementary use of liquid biopsy when tissue is unavailable.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S2 from Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy
Supplementary Fig. S2: Standard chemotherapy converts ICB-resistant ICCs to ICB-responsive tumors, significantly delays tumor progression and increases survival in mice.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S2 from Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy
Supplementary Fig. S2: Standard chemotherapy converts ICB-resistant ICCs to ICB-responsive tumors, significantly delays tumor progression and increases survival in mice.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S4 from Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy
Supplementary Fig. S4: IMC analysis of ICC after GC-based therapies in orthotopic murine 425-ICC model.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S4 from Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy
Supplementary Fig. S4: IMC analysis of ICC after GC-based therapies in orthotopic murine 425-ICC model.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S7 from Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy
Supplementary Fig. S7: Immunophenotyping in murine 425-ICC and SS49-ICC.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S7 from Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy
Supplementary Fig. S7: Immunophenotyping in murine 425-ICC and SS49-ICC.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S8 from Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy
Supplementary Fig. S8: Bulk tissue RNA sequencing analysis of ICC after GC/dual ICB combination therapy in orthotopic murine 425-ICC model.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S8 from Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy
Supplementary Fig. S8: Bulk tissue RNA sequencing analysis of ICC after GC/dual ICB combination therapy in orthotopic murine 425-ICC model.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S1 from Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy
Supplementary Fig. S1: Gating strategies for flow cytometry.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S1 from Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy
Supplementary Fig. S1: Gating strategies for flow cytometry.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S11 from Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy
Supplementary Fig. S11: Cxcr3 in CD8 T cells mediates the benefit of GC/ICB combination therapy in orthotopic murine 425-ICC model.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S11 from Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy
Supplementary Fig. S11: Cxcr3 in CD8 T cells mediates the benefit of GC/ICB combination therapy in orthotopic murine 425-ICC model.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S5 from Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy
Supplementary Fig. S5: CTLA-4 blockade is critical for efficacy of combined chemotherapy with ICB in ICC by grafting 425 murine cells in C57Bl/6/FVB F1 mice.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S5 from Reprogramming the Intrahepatic Cholangiocarcinoma Immune Microenvironment by Chemotherapy and CTLA-4 Blockade Enhances Anti–PD-1 Therapy
Supplementary Fig. S5: CTLA-4 blockade is critical for efficacy of combined chemotherapy with ICB in ICC by grafting 425 murine cells in C57Bl/6/FVB F1 mice.